TITLE

Beyond TNF, Th1 and Th2 in inflammatory bowel disease

AUTHOR(S)
Shale, Matthew; Ghosh, Subrata
PUB. DATE
October 2008
SOURCE
Gut;Oct2008, Vol. 57 Issue 10, p1349
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on the widespread use of a therapy utilizing antitumour necrosis factor (TNF) monoclonal antibodies for the treatment of Crohn's disease (CD) and ulcerative colitis (UC). It states that other therapies with anticytokines ability are in development, including against interleukin 6 (IL6), IL12/23 and interferon. It cites that targeting cytokines is based from observations regarding cytokine profile in the tissues of the intestine of patients with inflammatory bowel disease.
ACCESSION #
34640811

 

Related Articles

  • Use of Infliximab in Particular Clinical Settings: Management Based on Current Evidence. Papa, Alfredo; Mocci, Giammarco; Bonizzi, Michele; Felice, Carla; Andrisani, Gianluca; De Vitis, Italo; Guidi, Luisa; Gasbarrini, Antonio // American Journal of Gastroenterology;Jun2009, Vol. 104 Issue 6, p1575 

    With the increasingly widespread use of the anti-tumor necrosis factor-α agent infliximab for the treatment of Crohn's disease and ulcerative colitis, there have been some concerns raised about the potential consequences of such therapy in particular clinical settings. In this review, we...

  • Emerging Biologics in the Treatment of Inflammatory Bowel Disease: What is Around the Corner? Fiorino, Gionata; Rovida, Serena; Correale, Carmen; Malesci, Alberto; Danese, Silvio // Current Drug Targets;Feb2010, Vol. 11 Issue 2, p249 

    Inflammatory bowel diseases (IBD) are idiopathic chronic inflammations: the etiology of Crohn's disease (CD) and ulcerative colitis (UC) is still largely unknown. Environmental and genetic factors in combination with the microbial flora or specific microorganisms trigger an event, leading to the...

  • Infliximab: A Review of Its Use in the Treatment of Inflammatory Bowel Disease. Marzo, Manuela; Felice, Carla; Rapaccini, Gian Lodovico; Guidi, Luisa; Armuzzi, Alessandro // Clinical Medicine Insights: Therapeutics;2011, Issue 3, p15 

    Infliximab is a chimeric monoclonal antibody against anti-tumour necrosis factor alpha that has changed the management of inflammatory bowel diseases. Our review describes its mean clinical and pharmacological features, in order to resume its efficacy in induction and maintenance of clinical...

  • Mucosal Healing and anti TNFs in IBD. Assche, Gert van; Vermeire, S�verine; Rutgeerts, Paul // Current Drug Targets;Feb2010, Vol. 11 Issue 2, p227 

    Mucosal healing has been incorporated in the assessment of treatment efficacy in ulcerative colitis, but in Crohn's disease this concept has only emerged after biological therapies have been evaluated in clinical trials. Systemic steroids don't induce mucosal healing in Crohn's disease, but...

  • Current Therapeutic Approaches in Inflammatory Bowel Disease. Sohrabpour, Amir Ali; Malekzadeh, Reza; Keshavarzian, Ali // Current Pharmaceutical Design;11/28/2010, Vol. 16 Issue 33, p3668 

    No abstract available.

  • Ulcerative Colitis: A Cinderella Story. Danese, Silvio // Current Drug Targets;Sep2011, Vol. 12 Issue 10, preceding p1373 

    No abstract available.

  • Management of Crohn's disease in poor responders to adalimumab. de Boer, Nanne K. H.; Löwenberg, Mark; Hoentjen, Frank // Clinical & Experimental Gastroenterology;2014, Vol. 7, p83 

    Anti-tumor necrosis factor therapy with adalimumab is an effective therapy for the induction and maintenance of remission in moderate to severe Crohn's disease. Although a large proportion of patients show a favorable clinical response to adalimumab, therapy failure is common. In this review, we...

  • Efficacy of TNF Antagonists Beyond One Year in Adult and Pediatric Inflammatory Bowel Diseases: A Systematic Review. Oussalah, Abderrahim; Danese, Silvio; Peyrin-Biroulet, Laurent // Current Drug Targets;Feb2010, Vol. 11 Issue 2, p156 

    The introduction in the mid-1990s of tumor necrosis factor (TNF) antagonists changed the treatment of inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis (UC), refractory to conventional medications (corticosteroids, immunomodulators). This review summarizes current data on...

  • Lessons to Learn from Crohn's Disease Clinical Trials: Implications for Ulcerative Colitis. Jáuregui-Amézaga, Aránzazu; Ricart, Elena; Panés, Julián // Current Drug Targets;Sep2011, Vol. 12 Issue 10, p1467 

    The perception that Crohn's disease is a more severe process than ulcerative colitis, led to the initial development of a majority drugs, and testing of treatment strategies, in the former. In the absence of similar studies in ulcerative colitis, information of Crohn's disease studies may help...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics